Mrna Leading Expert Kenneth Chien And Novalis Lifesciences’ Marijn Dekkers Investing Eur 39M Series B2 Financing In Mrna Technology Platform Company Etherna
Amount Raised
€39 Million
Round Type
Series B
AntwerpenManufacturingBiotechnologyTherapeuticsDescription
eTheRNA (“the Company”), a leading mRNA technologies company, announced today that it has raised €39M in a Series B2 financing to expand investment in its integrated mRNA technology platform and further pursue its new initiatives for a partnership-driven business strategy. The round was led by Novalis LifeSciences with participation from Professor Kenneth Chien, a world-renowned expert in mRNA technology and its therapeutic applications. Existing investors, including LSP (now EQT Life Sciences), PMV, Grand Pharma, Fund+, Omega Fund, and others, also participated in the financing.
Quick answer
eTheRNA raised €39 Million in a Series B round, dated August 23, 2022. eTheRNA is based in Antwerpen, Antwerp, Belgium.
- How much did eTheRNA raise?
- eTheRNA raised €39 Million in a Series B round on August 23, 2022.
- What does eTheRNA do?
- By expanding its significant expertise in designing, synthesizing, and manufacturing cLNPs with a spectrum of properties suitable for a range of prophylactic and therapeutic indications, this innovative business model..
- Where is eTheRNA based and how big is it?
- eTheRNA is based in Antwerpen, Antwerp, Belgium. Fundz records about 96 employees.
- Who are the decision-makers at eTheRNA?
- Fundz holds 1 contact at eTheRNA. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Manufacturing around the same time
Companies in the same sectors as eTheRNA that raised within 45 days of this round, from Fundz verified event records.
- NewcelX raised $4M (Seed) on October 7, 2022.
- CASI Pharmaceuticals raised an undisclosed amount on September 23, 2022.
- RadioMedix raised $40M (Series A) on October 7, 2022.
- Valitor raised an undisclosed amount (Series B) on October 5, 2022.
- Vergent Bioscience raised $22M (Series B) on October 4, 2022.
- Sibylla Biotech raised $22M (Series A) on October 4, 2022.
Who to call at eTheRNA, and when
A new round usually means eTheRNA is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day eTheRNA raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at eTheRNA, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at eTheRNA. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment eTheRNA raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meanseTheRNA raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.